Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

271 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
Rosenberg AJ, Liao CY, Karrison T, de Souza JA, Worden FP, Libao B, Krzyzanowska MK, Hayes DN, Winquist E, Saloura V, Prescott K, Villaflor VM, Seiwert TY, Schechter RB, Stadler WM, Cohen EEW, Vokes EE. Rosenberg AJ, et al. Among authors: winquist e. Ann Oncol. 2023 Aug;34(8):714-722. doi: 10.1016/j.annonc.2023.05.002. Epub 2023 May 13. Ann Oncol. 2023. PMID: 37182801 Clinical Trial.
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L. Canil CM, et al. Among authors: winquist e. J Clin Oncol. 2005 Jan 20;23(3):455-60. doi: 10.1200/JCO.2005.02.129. J Clin Oncol. 2005. PMID: 15659491 Clinical Trial.
A Phase II study of oxaliplatin in urothelial cancer.
Winquist E, Vokes E, Moore MJ, Schumm LP, Hoving K, Stadler WM. Winquist E, et al. Urol Oncol. 2005 May-Jun;23(3):150-4. doi: 10.1016/j.urolonc.2004.11.008. Urol Oncol. 2005. PMID: 15907713 Clinical Trial.
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
Agulnik M, Cohen EW, Cohen RB, Chen EX, Vokes EE, Hotte SJ, Winquist E, Laurie S, Hayes DN, Dancey JE, Brown S, Pond GR, Lorimer I, Daneshmand M, Ho J, Tsao MS, Siu LL. Agulnik M, et al. Among authors: winquist e. J Clin Oncol. 2007 Sep 1;25(25):3978-84. doi: 10.1200/JCO.2007.11.8612. J Clin Oncol. 2007. PMID: 17761983 Clinical Trial.
271 results